601 related articles for article (PubMed ID: 31143186)
21. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
[TBL] [Abstract][Full Text] [Related]
22. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
[TBL] [Abstract][Full Text] [Related]
23. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
[TBL] [Abstract][Full Text] [Related]
24. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
25. Siglec-7 Defines a Highly Functional Natural Killer Cell Subset and Inhibits Cell-Mediated Activities.
Shao JY; Yin WW; Zhang QF; Liu Q; Peng ML; Hu HD; Hu P; Ren H; Zhang DZ
Scand J Immunol; 2016 Sep; 84(3):182-90. PubMed ID: 27312286
[TBL] [Abstract][Full Text] [Related]
26. Increased Frequency of Dysfunctional Siglec-7
Sakamoto Y; Yoshio S; Doi H; Mori T; Matsuda M; Kawai H; Shimagaki T; Yoshikawa S; Aoki Y; Osawa Y; Yoshida Y; Arai T; Itokawa N; Atsukawa M; Ito T; Honda T; Mise Y; Ono Y; Takahashi Y; Saiura A; Taketomi A; Kanto T
Front Immunol; 2021; 12():603133. PubMed ID: 33692781
[TBL] [Abstract][Full Text] [Related]
27. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms.
Nicoll G; Avril T; Lock K; Furukawa K; Bovin N; Crocker PR
Eur J Immunol; 2003 Jun; 33(6):1642-8. PubMed ID: 12778482
[TBL] [Abstract][Full Text] [Related]
28. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
29. Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.
Belisle JA; Horibata S; Jennifer GA; Petrie S; Kapur A; André S; Gabius HJ; Rancourt C; Connor J; Paulson JC; Patankar MS
Mol Cancer; 2010 May; 9():118. PubMed ID: 20497550
[TBL] [Abstract][Full Text] [Related]
30. High-affinity ligands of Siglec receptors and their therapeutic potentials.
Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
[TBL] [Abstract][Full Text] [Related]
31. Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis.
Büll C; Heise T; Adema GJ; Boltje TJ
Trends Biochem Sci; 2016 Jun; 41(6):519-531. PubMed ID: 27085506
[TBL] [Abstract][Full Text] [Related]
32. Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S; Chevalier MF; Villier L; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
Eur Urol Open Sci; 2021 Dec; 34():79-82. PubMed ID: 34825225
[TBL] [Abstract][Full Text] [Related]
33. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
34. Quantitative Analysis of Siglec Ligands by Flow Cytometry.
Chang LY; Sridharan D; Angata T
Curr Protoc; 2023 Dec; 3(12):e949. PubMed ID: 38050649
[TBL] [Abstract][Full Text] [Related]
35. Probing the cis interactions of the inhibitory receptor Siglec-7 with alpha2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of alpha2,8-sialyltransferase gene expression.
Avril T; North SJ; Haslam SM; Willison HJ; Crocker PR
J Leukoc Biol; 2006 Oct; 80(4):787-96. PubMed ID: 16857734
[TBL] [Abstract][Full Text] [Related]
36. Sialylated IgG in epithelial cancers inhibits antitumor function of T cells via Siglec-7.
Fan T; Liao Q; Zhao Y; Dai H; Song S; He T; Wang Z; Huang J; Zeng Z; Guo H; Zhang H; Qiu X
Cancer Sci; 2023 Feb; 114(2):370-383. PubMed ID: 36310398
[TBL] [Abstract][Full Text] [Related]
37. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
38. Siglecs in Brain Function and Neurological Disorders.
Siddiqui SS; Matar R; Merheb M; Hodeify R; Vazhappilly CG; Marton J; Shamsuddin SA; Al Zouabi H
Cells; 2019 Sep; 8(10):. PubMed ID: 31546700
[TBL] [Abstract][Full Text] [Related]
39. Leishmania donovani Utilize Sialic Acids for Binding and Phagocytosis in the Macrophages through Selective Utilization of Siglecs and Impair the Innate Immune Arm.
Roy S; Mandal C
PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004904. PubMed ID: 27494323
[TBL] [Abstract][Full Text] [Related]
40. Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer.
Wen R; Zhao H; Zhang D; Chiu CL; Brooks JD
Carbohydr Res; 2022 Sep; 519():108598. PubMed ID: 35691122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
